Mantle Cell Lymphoma
338
64
106
139
Key Insights
Highlights
Success Rate
77% trial completion
Published Results
85 trials with published results (25%)
Research Maturity
139 completed trials (41% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
12.1%
41 terminated out of 338 trials
77.2%
-9.3% vs benchmark
8%
27 trials in Phase 3/4
61%
85 of 139 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 139 completed trials
Clinical Trials (338)
A Long-term Extension Study of PCI-32765 (Ibrutinib)
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy
Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy
HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell Lymphoma
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies